Law360, New York (June 03, 2010, 4:21 PM ET) -- The U.S. Securities and Exchange Commission has filed a lawsuit alleging a former executive of Sequenom Inc. falsely claimed that a prenatal test the company made could predict with 100 percent accuracy whether a fetus had Down syndrome, holding her responsible for the stock price plummet that occurred when data was revealed to be untrue.
In a complaint filed Wednesday in the U.S. District Court for the Southern District of California, the SEC accused former Sequenom Senior Vice President of Research and Development Elizabeth Dragon of...
Sequenom VP Inflated Down Syndrome Test: SEC
To view the full article, take a free trial now.
